Clinical utility of cell-free urine miR-93-5p, miR-191-5p, miR-31-5p for invasive urothelial carcinoma detection and immune signature-based subtyping

This study aimed to explore the potential value of urinary cell-free microRNA (miR)-93-5p, miR-191-5p, and miR-31-5p levels in the non-invasive prediction of basal-like and luminal-like invasive urothelial carcinoma immune signature phenotypes according to the molecular classification of bladder cancer, by comparing their expression in patients and healthy controls. The study included morning urine samples from 49 bladder cancer patients and 43 controls. A quantitative image-based immunohistochemical analysis classified tumor cases into basal-like and luminal-like subtypes. Quantitative real-time PCR (qRT-PCR) was used to measure cell-free miR-93-5p, miR-191-5p, and miR-31-5p expression levels in urine. MiR-191-5p was significantly downregulated in bladder cancer patients compared to healthy controls (p < 0.001), with a 24-fold decrease. Notably, miR-191-5p levels were markedly lower in the luminal-like subtype relative to the control group (p < 0.001). In contrast, miR-93-5p was significantly upregulated in the basal-like subtype, showing a 4.15-fold increase compared to controls (p < 0.001). Elevated levels of miR-93-5p were also observed in high-grade tumors (3.4-fold, p = 0.004), in tumors exhibiting necrosis (3.4-fold, p < 0.001), and in the presence of carcinoma in situ (CIS) (2.6-fold, p = 0.02). Furthermore, miR-93-5p levels showed a positive correlation with tumor size (r = 0.41, p < 0.001). In this exploratory cohort, miR-93-5p also demonstrated strong discriminatory performance in identifying CK5/6-positive tumors, with a receiver operating characteristic (ROC) curve cut-off value of 1.57 for 2^ΔΔCT value. In this single-center, exploratory study, urinary cell-free miR-93-5p and miR-191-5p showed potential utility as non-invasive biomarkers for rapid molecular subtype identification in bladder cancer. miR-93-5p was associated with basal-like (aggressive) tumor features, while miR-191-5p was inversely associated with invasive urothelial carcinoma. miR-31-5p appears to serve as a complementary marker, especially in cases of CIS.

Authors

Institutions

Publication Details

Journal
BMC Urology
Published
2026-01-15
DOI
https://doi.org/10.1186/s12894-026-02047-y
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical utility of cell-free urine miR-93-5p, miR-191-5p, miR-31-5p for invasive urothelial carcinoma detection and immune signature-based subtyping

Çetin Demirdağ, Sami Berk Özden, İpek Sertbudak, Furkan Kuzucu et al.
BMC Urology
Bladder and Urothelial Cancer Treatments
article

Clinical utility of cell-free urine miR-93-5p, miR-191-5p, miR-31-5p for invasive urothelial carcinoma detection and immune signature-based subtyping

Çetin Demirdağ, Sami Berk Özden, İpek Sertbudak, Furkan Kuzucu, Iclal Gurses, Aysel Kalaycı, Filiz Özdemir
article en

Abstract

This study aimed to explore the potential value of urinary cell-free microRNA (miR)-93-5p, miR-191-5p, and miR-31-5p levels in the non-invasive prediction of basal-like and luminal-like invasive urothelial carcinoma immune signature phenotypes according to the molecular classification of bladder cancer, by comparing their expression in patients and healthy controls. The study included morning urine samples from 49 bladder cancer patients and 43 controls. A quantitative image-based immunohistochemical analysis classified tumor cases into basal-like and luminal-like subtypes. Quantitative real-time PCR (qRT-PCR) was used to measure cell-free miR-93-5p, miR-191-5p, and miR-31-5p expression levels in urine. MiR-191-5p was significantly downregulated in bladder cancer patients compared to healthy controls (p < 0.001), with a 24-fold decrease. Notably, miR-191-5p levels were markedly lower in the luminal-like subtype relative to the control group (p < 0.001). In contrast, miR-93-5p was significantly upregulated in the basal-like subtype, showing a 4.15-fold increase compared to controls (p < 0.001). Elevated levels of miR-93-5p were also observed in high-grade tumors (3.4-fold, p = 0.004), in tumors exhibiting necrosis (3.4-fold, p < 0.001), and in the presence of carcinoma in situ (CIS) (2.6-fold, p = 0.02). Furthermore, miR-93-5p levels showed a positive correlation with tumor size (r = 0.41, p < 0.001). In this exploratory cohort, miR-93-5p also demonstrated strong discriminatory performance in identifying CK5/6-positive tumors, with a receiver operating characteristic (ROC) curve cut-off value of 1.57 for 2^ΔΔCT value. In this single-center, exploratory study, urinary cell-free miR-93-5p and miR-191-5p showed potential utility as non-invasive biomarkers for rapid molecular subtype identification in bladder cancer. miR-93-5p was associated with basal-like (aggressive) tumor features, while miR-191-5p was inversely associated with invasive urothelial carcinoma. miR-31-5p appears to serve as a complementary marker, especially in cases of CIS.

BMC UrologyVol. 26(1)
Osmaniye Korkut Ata University (TR), Istanbul University-Cerrahpaşa (TR), Istanbul University (TR)
Reduced inequalities
Openalex Percentile: Top 88%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.